Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLC Followed by CR-CHOP in Elderly Double-expressor Lymphoma
NCT06674096Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in double-expressor lymphoma (DEL), sponsored by Zhejiang Cancer Hospital. Started Nov 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
double-expressor lymphoma (DEL)
Beyond the preview
Go deeper on NCT06674096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674096.